Clinical trials: Locally Advanced Gastric Cancer
Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)
The purpose of this study was to demonstrate superiority of treatment with avelumab versus continuation of first-line chemotherapy.
- Trial name
- NCT02625610
- Testing
- Avelumab, Oxaliplatin, 5-Fluorouracil
- Where
- 200 sites in United States, Australia and 15 more
- Volunteers
- 499 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Gastric Cancer (Diagnosis), Gastroesophageal Junction Adenocarcinoma
TAIC FOLFOX for Locally Advanced G/GEJA
Gastric cancer is the fifth most common malignancy worldwide in terms of both incidence and mortality. The majority of cases are diagnosed at advanced stage-often presenting with severe complications such as malignant stricture…
- Trial name
- TFLAG (NCT07655024)
- Testing
- TAIC, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Gastro-Oesophageal Cancer
A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer
A randomised phase III, double-blind, placebo-controlled trial with 2:1 (regorafenib : placebo)
- Trial name
- INTEGRATEIIa (NCT02773524)
- Testing
- Regorafenib
- Where
- 60 sites in United States, Australia and 5 more
- Volunteers
- 250 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Gastroenteropancreatic Neuroendocrine Tumor
Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
This study will be conducted to support the registration of the lanreotide Autogel 120 mg formulation in China for the treatment of GEP-NETs and treatment of clinical symptoms of NETs.
- Trial name
- PALACE (NCT04852679)
- Testing
- Lanreotide autogel
- Where
- 14 sites in China
- Volunteers
- 43 people
- Sponsor
- Ipsen
Gastric Cancer
A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Advanced or Metastatic Gastric Cancer.
This single arm study will assess the efficacy and safety of Xeloda in combination with oxaliplatin as first-line chemotherapy in patients with advanced and/or metastatic gastric cancer who have had no prior chemotherapy for…
- Trial name
- NCT00436241
- Testing
- Oxaliplatin, capecitabine [Xeloda]
- Where
- 13 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer, Gastric Cancer
Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers
It is planned to study the effectiveness of low-dose immunotherapy (IT) nivolumab 40 mg for either 2 courses of therapy or 6 courses as preoperative therapy in patients with dMMR/MSI locally advanced CRC.
- Trial name
- NIVO402025 (NCT07542262)
- Testing
- Low-dose nivolumab, Low-dose nivolumab with/without chemotherapy, Low-dose nivolumab combined with chemotherapy
- Where
- Russia
- Volunteers
- 128 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Stomach Neoplasm
A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer
Gastric cancer is the fifth most common carcinoma in the world, and cancer-related deaths rank third. It is one of the main causes of death from cancer in Korea.
- Trial name
- NCT05184803
- Testing
- Docetaxel injection, oxaliplatin, S-1
- Where
- South Korea
- Volunteers
- 63 people
- Sponsor
- Asan Medical Center
Stomach Neoplasms
Docetaxel and Oxaliplatin in Gastric Cancer
This phase II study addressed the use of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced…
- Trial name
- NCT00382720
- Testing
- Docetaxel + Oxaliplatin, Docetaxel + Oxaliplatin + 5-FU, Docetaxel + Oxaliplatin + Capecitabine
- Where
- 12 sites in United States, Belgium and 10 more
- Volunteers
- 275 people
- Sponsor
- Sanofi
Gastric Cancer, Chemotherapy Effect
Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer
The trial is a prospective, randomized, controlled phase Ⅱ study which will be conducted in Chinese PLA General Hospital, Beijing, China.
- Trial name
- NCT04782791
- Testing
- Nivolumab plus SOX, Nivolumab, Gastrectomy
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Gastric Cancer, Neoadjuvant Chemotherapy
Appraisal of the Modified Cancer Cachexia Index in Locally Advanced Gastric Cancer Patients Undergoing Neoadjuvant Chemotherapy
In this study, consecutive 600 patients with LAGC(cT2-4NanyM0) who underwent NACT between Jan. 2010 and Jun. 2022 were identified from two tertiary hospitals.
- Conditions
- Gastric Cancer, Neoadjuvant Chemotherapy, Computed Tomography, Random Forest Model
- Trial name
- NCT06689462
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Fujian Medical University